David Badawi Sells 5,980 Shares of Sight Sciences, Inc. (NASDAQ:SGHT) Stock

Sight Sciences, Inc. (NASDAQ:SGHT) CTO David Badawi sold 5,980 shares of the stock in a transaction that occurred on Tuesday, April 1st. The stock was sold at an average price of $2.30, for a total value of $13,754.00. Following the transaction, the chief technology officer now directly owns 1,836,704 shares of the company’s stock, valued at approximately $4,224,419.20. This trade represents a 0.32 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website.

David Badawi also recently made the following trade(s):

• On Friday, January 17th, David Badawi sold 5,423 shares of Sight Sciences stock. The stock was sold at an average price of $2.78, for a total value of $15,075.94.
• On Wednesday, January 8th, David Badawi sold 3,829 shares of Sight Sciences stock. The shares were sold at an average price of $3.26, for a total value of $12,482.54.
• On Friday, January 3rd, David Badawi sold 3,111 shares of Sight Sciences stock. The stock was sold at an average price of $3.52, for a total transaction of $10,950.72.

Sight Sciences Stock Up 3.1 %

SGHT opened at $2.30 on Friday. The firm has a market cap of $118.07 million, a P/E ratio of -2.25 and a beta of 2.52. The business’s fifty day simple moving average is $2.67 and its 200 day simple moving average is $3.86. Sight Sciences, Inc. has a 52 week low of $2.04 and a 52 week high of $8.45. The company has a quick ratio of 9.74, a current ratio of 10.18 and a debt-to-equity ratio of 0.36.

Sight Sciences (NASDAQ:SGHT) last announced its quarterly earnings data on Wednesday, March 5th. The company reported ($0.23) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.22) by ($0.01). The firm had revenue of $19.07 million for the quarter, compared to analysts’ expectations of $18.98 million. Sight Sciences had a negative net margin of 63.30% and a negative return on equity of 47.28%. During the same period in the previous year, the company posted ($0.22) EPS. As a group, equities research analysts anticipate that Sight Sciences, Inc. will post -0.99 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research firms recently commented on SGHT. Needham & Company LLC reissued a “hold” rating on shares of Sight Sciences in a report on Thursday, March 6th. UBS Group lowered their price target on Sight Sciences from $5.50 to $5.00 and set a “buy” rating on the stock in a report on Monday, January 27th. Piper Sandler reduced their price objective on Sight Sciences from $5.50 to $3.50 and set a “neutral” rating for the company in a report on Thursday, March 6th. Citigroup lowered their target price on Sight Sciences from $4.60 to $3.00 and set a “neutral” rating on the stock in a report on Tuesday, March 4th. Finally, Stifel Nicolaus cut their price target on Sight Sciences from $5.00 to $4.00 and set a “buy” rating for the company in a research note on Thursday, March 6th. Five investment analysts have rated the stock with a hold rating and two have assigned a buy rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Hold” and an average price target of $3.83.

Institutional Investors Weigh In On Sight Sciences

A number of hedge funds and other institutional investors have recently made changes to their positions in SGHT. ProShare Advisors LLC purchased a new position in Sight Sciences during the fourth quarter worth about $36,000. Dynamic Technology Lab Private Ltd purchased a new position in shares of Sight Sciences during the 4th quarter worth about $40,000. Arkadios Wealth Advisors acquired a new stake in shares of Sight Sciences in the fourth quarter worth approximately $47,000. WealthTrust Asset Management LLC purchased a new stake in Sight Sciences in the fourth quarter valued at approximately $48,000. Finally, Mitsubishi UFJ Asset Management Co. Ltd. acquired a new position in Sight Sciences during the fourth quarter worth approximately $50,000. Hedge funds and other institutional investors own 55.51% of the company’s stock.

Sight Sciences Company Profile

Sight Sciences, Inc, an ophthalmic medical device company, engages in the development and commercialization of surgical and nonsurgical technologies for the treatment of eye diseases. It operates through two segments, Surgical Glaucoma and Dry Eye. The company's products include OMNI Surgical System, an implant-free glaucoma surgery technology indicated to reduce intraocular pressure in adult patients with primary open-angle glaucoma; and SION Surgical Instrument, a manually operated device used in ophthalmic surgical procedures to excise trabecular meshwork.